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Abstract: Ochratoxins, patulin, deoxynivalenol, and T-2 toxin are mycotoxins, and common
contaminants in food and drinks. Human serum albumin (HSA) forms complexes with certain
mycotoxins. Since HSA can affect the toxicokinetics of bound ligand molecules, the potential
interactions of ochratoxin B (OTB), ochratoxin C (OTC), patulin, deoxynivalenol, and T-2 toxin
with HSA were examined, employing spectroscopic (fluorescence, UV, and circular dichroism)
and ultrafiltration techniques. Furthermore, the influence of albumin on the cytotoxicity of these
xenobiotics was also evaluated in cell experiments. Fluorescence studies showed the formation of
highly stable OTB–HSA and OTC–HSA complexes. Furthermore, fluorescence quenching and circular
dichroism measurements suggest weak or no interaction of patulin, deoxynivalenol, and T-2 toxin
with HSA. In ultrafiltration studies, OTB and OTC strongly displaced the Sudlow’s site I ligand
warfarin, while other mycotoxins tested did not affect either the albumin binding of warfarin or
naproxen. The presence of HSA significantly decreased or even abolished the OTB- and OTC-induced
cytotoxicity in cell experiments; however, the toxic impacts of patulin, deoxynivalenol, and T-2 toxin
were not affected by HSA. In summary, the complex formation of OTB and OTC with albumin is
relevant, whereas the interactions of patulin, deoxynivalenol, and T-2 toxin with HSA may have low
toxicological importance.
Keywords: ochratoxin B; ochratoxin C; patulin; deoxynivalenol; T-2 toxin; human serum albumin;
fluorescence spectroscopy; optical spectroscopy; albumin–ligand interaction; cytotoxicity
Key Contribution: Ochratoxin B and C bind tightly to human serum albumin. In contrast, the role of
albumin in the toxicokinetics of patulin, deoxynivalenol, and T-2 toxin seems to be negligible.
1. Introduction
Mycotoxins are secondary fungal metabolites, which commonly contaminate food and feed,
causing different toxic effects in animals and humans [1]. Ochratoxins are produced by Aspergillus and
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Penicillium species, containing a dihydroisocoumarin moiety linked to L-phenylalanine (Figure 1) [2].
These nephrotoxic agents appear as contaminants in grains, cereal-based commodities, fruits, spices,
and beverages (e.g., wine, beer, milk, and coffee) [3,4]. Among ochratoxins, ochratoxin A occurs
most frequently; however, its dechlorinated and ethyl ester derivatives—ochratoxin B (OTB) and
ochratoxin C (OTC), respectively—seem to be also important (Figure 1). OTC is a similarly toxic
to ochratoxin A, while OTB is less toxic [4]. Patulin (PAT; Figure 1) is produced by Aspergillus and
Penicillium species. Due to its antiviral, antifungal, and antibacterial activities, PAT was used in the
treatment of common cold and skin infections in the 1940s. However, it has been classified as a toxin
from the 1960s, due to its harmful effects [5]. PAT frequently appears in blue mold contaminated apples,
pears, and related products (e.g., apple juice, compotes, ciders, and baby food puree) [6]. Excitement,
convulsions, dyspnea, pulmonary congestion, edema, ulceration, and gastrointestinal tract distension
can be the symptoms of acute PAT intoxication [7]. After chronic exposure, PAT may induce genotoxic,
teratogenic, and immunotoxic effects [6]. Trichothecene mycotoxins (containing 2,13-epoxytrichothene
moiety) are produced by several filamentous fungi, including Fusarium, Myrothecium, Phomopsis,
Stachybotrys, and Trichoderma species [5]. Deoxynivalenol (DON or also called as vomitoxin; Figure 1) is
one of the most common trichothecene contaminants in cereals (e.g., wheat, barley, corn, and rye) and
in related products (e.g., flour, bread, and beer) [5]. Low dose intake of DON can lead to weight loss,
whereas high doses exert gastrointestinal disorders (e.g., nausea, vomiting, and diarrhea) [5,8]. Chronic
exposure to DON induces cytotoxic, immunotoxic, and genotoxic effects as well as reproductive
disorders [9]. Among trichothecenes, T-2 toxin (T2; Figure 1) is one of the most cytotoxic [10]. T2 can
provoke immunosuppressive, gastrointestinal, dermatological, and neurological symptoms [5,11–13].
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2. Results and Discussion 
2.1. Fluorescence Spectroscopic Investigation of the Interactions of OTB and OTC with HSA 
The fluorescence quenching effects of OTB and OTC on HSA (2 µM) were studied in the presence 
of increasing mycotoxin concentrations (0–2 µM). OTB and OTC decreased the emission signal of 
HSA at 340 nm in a concentration-dependent fashion (Figure 2A,B). Since the inner filter effect of 
ochratoxins was negligible (the corrections were performed based on Equation 1), these observations 
suggest the formation of mycotoxin–HSA complexes. Based on the strong quenching effects of OTB 
and OTC on HSA, these mycotoxins occupy a binding site close to the Trp-214 residue. Therefore, it 
is reasonable to conclude that the high-affinity binding site of OTB and OTC is located at Sudlow’s 
site I (subdomain IIA), similar to the parent mycotoxin ochratoxin A [30,31]. The appearance of 
increasing second peaks at 430 (Figure 2A) and 444 nm (Figure 2B) are due to the intrinsic 
fluorescence of OTB and OTC, respectively. Stern–Volmer plots of OTB–HSA and OTC–HSA 
interactions are shown in Figure 2C. 
Fig re 1. e ical str ct res of oc ratoxi ( ), oc ratoxi ( ), oc ratoxi ( ), at li
( T), deoxynivalenol (DON), and T-2 toxin (T2).
Human serum albumin (HSA) is the dominant circulating plasma protein. Albumin–ligand
interactions result in the partial entrapment of ligand molecules, which may influence the toxicokinetics
of HSA-bound xenobioti s [14,15]. Most of the compounds occupy one of the three major drug binding
sites on HSA: Sudlow’s site I, Sudlow’s site II, and the heme binding site (or FA1) [14,16]. Albumin
binds tightly several mycotoxins, including alternariol, citrinin, ochratoxin A, and zearalenone [17–20].
The interaction of ochratoxin A with HSA has been extensively studied [17,21–23], however, only limited
data are available regarding other ochratoxins. Despite the fact that these mycotoxins frequently appear
in food and animal feed (and consequently, in the body fluids of humans and animals), the interactions
of OTB, OTC, DON, PAT, and T2 with HSA were not or only barely investigated. Previous reports
suggest that OTB, DON, and PAT bind to the site I (subdomain IIA) of HSA, showing approximately
1.8 × 106 L/mol [22], 4.6 × 104 L/mol [24], and 1.4 × 104 L/mol [25] association constants, respectively.
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Only one individual study was reported regarding each mycotoxin–HSA interaction, employing
spectroscopic and molecular docking studies [22,24,25]. To the best of our knowledge, the interaction
of OTC and T2 with HSA has not yet been evaluated. Additionally, some toxicokinetic aspects of
mycotoxins are poorly examined and/or understood. In our view, the importance of mycotoxin–albumin
complexes is underestimated. Besides the interactions of mycotoxins with biotransformation enzymes
and drug transporters, their albumin binding seems to be a relevant factor as well. Considering the
stability of the formed complexes, their toxicological importance can be estimated [15,21]; however,
other factors should also be considered. Furthermore, the binding location of a mycotoxin on albumin
predicts which compounds are able to displace it from the protein. If the albumin-bound fraction of
a mycotoxin is high in the circulation, the displacement may cause significant changes in its tissue
distribution and/or elimination, and consequently, in its toxicity. In addition, the species differences
in albumin binding may help to understand the high species-dependent alternations in the toxicity
of certain mycotoxins (e.g., zearalenone and its metabolites) [19,26]. Generally, mycotoxin–albumin
interactions are barely examined, and most studies apply only spectroscopic techniques. Despite the
fact that fluorescence and UV–Vis spectroscopy are powerful techniques to examine protein–ligand
interactions, we need to consider their limitations, which can explain some controversial results
reported for some mycotoxins (e.g., aflatoxin B1) [27–29]. Therefore, other methodologies are also
required to obtain well-established conclusions, and extensive in vitro experiments as well as animal
studies need to be performed for deeper understanding of mycotoxin–albumin interactions.
In this study, the complex formation of OTB, OTC, PAT, DON, and T2 with HSA was examined
employing fluorescence spectroscopy, ultrafiltration, and cell experiments. Because PAT, DON, and T2
have no intrinsic fluorescence, their interactions were investigated by using circular dichroism (CD)
and UV spectroscopy. In previous studies [22,24,25], the complex formation of OTB, PAT, and DON
with HSA were examined with spectroscopic techniques. Because the application of other methods
is also reasonable to confirm these results, in the current study. Cell experiments are important to
test the effect of albumin binding on the cellular uptake and cytotoxicity of xenobiotics. Besides the
interaction with albumin, several other factors can influence the tissue uptake of mycotoxins, such as
the diffusibility of the compound and the involvement of active transport mechanisms. Thus, even if
the binding constant of an albumin–ligand complex is known, cell experiments are useful for the more
precise prediction of the importance of albumin binding in tissue uptake. Since hepatocytes express
several drug transporters which can be involved in the cellular uptake of mycotoxins, HepG2 liver
cells were used in these experiments. Therefore, to test the toxicological importance of the albumin
binding of OTB, OTC, PAT, DON, and T2, the effects of fetal bovine serum (10%) and HSA (40 g/L) on
the acute in vitro toxicity of mycotoxins were studied.
2. Results and Discussion
2.1. Fluorescence Spectroscopic Investigation of the Interactions of OTB and OTC with HSA
The fluorescence quenching effects of OTB and OTC on HSA (2 µM) were studied in the presence
of increasing mycotoxin concentrations (0–2 µM). OTB and OTC decreased the emission signal of HSA
at 340 nm in a concentration-dependent fashion (Figure 2A,B). Since the inner filter effect of ochratoxins
was negligible (the corrections were performed based on Equation (1)), these observations suggest the
formation of mycotoxin–HSA complexes. Based on the strong quenching effects of OTB and OTC on HSA,
these mycotoxins occupy a binding site close to the Trp-214 residue. Therefore, it is reasonable to conclude
that the high-affinity binding site of OTB and OTC is located at Sudlow’s site I (subdomain IIA), similar to
the parent mycotoxin ochratoxin A [30,31]. The appearance of increasing second peaks at 430 (Figure 2A)
and 444 nm (Figure 2B) are due to the intrinsic fluorescence of OTB and OTC, respectively. Stern–Volmer
plots of OTB–HSA and OTC–HSA interactions are shown in Figure 2C.
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increased with the elevation of HSA concentration (Figure 3), and the relative increase in the 
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435 nm) was observed in the emission wavelength maximum of OTB, as was also reported by Perry 
et al. [22]. HSA caused a similar shift in the emission spectrum of OTC (444 → 447 nm). As it is 
demonstrated in Figure 3C,D, lower HSA concentrations were enough to achieve the complete 
albumin binding of OTC vs. OTB (approximately 2–3 vs. 5–7 μM, respectively), suggesting that HSA 
forms more stable complexes with OTC. 
Figure 2. Fluorescence quenching effects of ochratoxins on human serum albumin (HSA). Emission
spectra of HSA (2 µM) in the presence of increasing concentrations of ochratoxin B (OTB;
(A); ex slit = 5 nm, em slit = 10 nm) and ochratoxin C (OTC; (B); ex slit = 10 nm, em slit = 10 nm) in
phosphate-buffered saline (PBS, pH 7.4; λex = 295 nm). Stern–Volmer plots of OTB–HSA and OTC–HSA
co plexes (C) (λem = 340 n ; RLU: relative light unit).
the next step, increasing amounts of HSA (0–7.5 µM) were added to 1 µM mycotoxin. Similarly
to the previous report with ochratoxin A and 2′R-ochratoxin A [23], these samples were applied for
three different fluorescence measur m nts (ma ked below as I, II, and III).
(I) irst, 365 (OTB) and 380 nm (OTC) excitation wavel ngths wer used to est the eff ct of HSA on
the intrinsic fluorescence of ochrat xins. Emi sion signals of both OTB and OTC significantly increased
with th elevation of HSA concentration (Figure 3), and the relative increase in the fluore cence of
OTB was larger compared to OTC. I ortantly, under the applied circumstances, HSA did no show
emission signal. Th se observations sugg st again he formation of ochratoxin– lbumin complexes.
Because the fluorescence of aromatic fluorophores can be partly quenched by water molecules [32],
the binding of OTB and OTC to HSA results in the partial decomposi ion of heir hydration shell.
Consequently, the quenching effect of water molecules decreases and the emission signal of t
mycotoxins rises [18,20,23]. In the p esence of HSA, a slight d shift (430→ 435 nm) was observed in
the emission wavelength maxi um of OTB, as was also reported by Perry et l. [22]. HSA caus d a
similar shift in the emission spectrum of OTC (444→ 447 nm). As it is demonstrated in Figure 3C,D,
lower HSA concentrations were enough to a hieve he compl te albumin binding of OTC vs. OTB
(approximately 2–3 vs. 5–7 µM, respectively), suggesting that HSA forms more stable complexes
with OTC.
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1 μM; λex = 380 nm; ex slit = 5 nm, em slit = 10 nm) in the presence of increasing human serum albumin 
(HSA) concentrations in phosphate‐buffered saline (PBS, pH 7.4). HSA‐induced increase in the 
emission intensities of OTB (C) and OTC (D) at 430 and 444 nm, respectively (RLU: relative light unit). 
The emission intensity of OTB and OTC did not increase further above 7.5 and 3 μM HSA 
concentrations, respectively. 
(II) In the next experiment, fluorescence emission signals of OTB and OTC were examined again; 
however, the emission spectra were recorded using the excitation maximum of Trp‐214 in HSA (295 
nm). The first peak, with the maximum at 340 nm, is the emission signal of HSA. Because the 
fluorescence emission spectrum of Trp‐214 overlaps with the excitation spectra of OTB and OTC, and 
the binding sites of ochratoxins are close to the Trp‐214 residue, the energy transfer between HSA 
and ochratoxins leads to the increase in the emission signal around 430–450 nm (Figure 4A,B). These 
results also demonstrate the stronger interaction of HSA with OTC compared to OTB (Figure 4C,D). 
Figure 3. Effects of HSA on the fluorescence of ochratoxins. Fluorescence emission spectra of ochratoxin
B (OTB; (A); 1 µM; λex = 365 nm; ex slit = 5 nm, em slit = 5 nm) and ochratoxin C (OTC; (B);
1 µ ; λex = 380 nm; ex slit = 5 n , em slit = 10 nm) in the presence of increasing hu an serum
albumin (HSA) concentrations in phosphate-buffered saline (PBS, p 7.4). HSA-induced increase
in the emission intensities of OTB (C) and OTC (D) at 430 and 444 nm, respectively (RLU: relative
light unit). The emission intensity of OTB and OTC did not increase further above 7.5 and 3 µM S
concentrations, respectively.
t e t ex eri t, fl r i i i l f a T ere exa ine again;
t e e is ion spectra were recorded using the excitation maximu of Trp-214 in HSA (295 nm).
The first peak, with the maximu at 340 nm, is the emis ion signal of HSA. Because the fluore cenc
emission spectrum f Trp-214 overla s with the excitation sp ctra of OTB and OTC, and the bindi g
sites of ochratoxins are close to the Trp-214 residue, the energy transfer between HSA and ochratoxins
leads to the cr se in emission signal around 430–450 nm (Figure 4A,B). These results al o
demonstrate the strong r interaction of HSA with OTC compared to OTB (Figure 4C,D).
(III) Finally, fluorescence anisotropy values of the samples were also determined (OTB:
λex = 365 nm, λem = 430 nm; OTC: λex = 380 nm, λem = 444 nm). Fluorescence anisotropy is
affected by the rotational freedom of the molecules in an inversely proportional manner [33]. The small
molecules (e.g., OTB and OTC) possess high rotational freedom accompanied with low anisotropy
values. However, the complex formation with HSA decreases their rotational freedom, which leads
to a large elevation in anisotropy [23,34]. Fluorescence anisotropy values of OTB and OTC strongly
increased in the presence of HSA (Figure 5), confirming their protein binding as well as the higher
affinity of OTC.
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Figure 4. Assessment of ochratoxin–albumin interactions based on energy transfer between Trp-214
and mycotoxins (unlike Figure 3, samples were excited at 295 nm). Fluorescence emission spectra
of ochratoxin B (OTB; (A); 1 µM; ex slit = 5 nm, em slit = 10 nm) and ochratoxin C (OTC; (B);
1 µM; ex slit = 5 nm, em slit = 10 nm) in the presence of increasing human serum albumin (HSA)
concentrations in phosphate-buffered saline (PBS, pH 7.4; λex = 295 nm). Emission intensities of OTB
(C) and OTC (D) at 430 and 444 nm, respectively: these data were corrected by subtracting the emission
signal of HSA at the wavelengths used (RLU: relative light unit). The emission intensity of TB and
OTC did not increase further above 7.5 and 3 µM HSA concentrations, respectively.
Toxins 2020, 12, x FOR PEER REVIEW 7 of 18 
 
 
Figure 5. Fluorescence anisotropy values of ochratoxin B (OTB; 1 μM; λex = 365 nm, λem = 430 nm) and 
ochratoxin C (OTC; 1 μM; λex = 380 nm, λem = 444 nm) in the presence of increasing human serum 
albumin (HSA) concentrations in phosphate‐buffered saline (PBS, pH 7.4; ex slit = 10 nm, em slit = 10 
nm). The fluorescence anisotropy of OTB and OTC did not increase further above 3 μM HSA 
concentration. 
Based on fluorescence measurements, Stern–Volmer quenching constants (KSV; unit: L/mol) and 
association constants (Ka; unit: L/mol) of ochratoxin–HSA complexes were determined (see details in 
4.2). Both OTB and OTC form highly stable complexes with HSA. Only quenching studies proposed 
somewhat lower association constants; however, the other three methods showed good correlations, 
suggesting approximately 106 and 107 L/mol association constants of OTB–HSA and OTC–HSA 
complexes, respectively (Table 1). These data are in agreement with the previously reported 
association constant for the OTB–HSA complex (Ka = 1.80 × 106 L/mol) by Perry et al. [22]. This finding 
demonstrates that the stability of OTC–HSA is one magnitude higher compared to the OTB–HSA 
complex (Table 1). Thus, OTB and OTC form significantly less and similarly stable complexes with 
HSA than ochratoxin A, respectively. Nevertheless, even the binding affinity of OTB toward HSA 
can be considered high. Based on these observations, both the absence of chlorine substituent (OTB) 
and the presence of ethyl substituent (OTC) decrease the stability of ochratoxin–HSA complexes. 
Previous data indicate extremely strong interaction of ochratoxin A with HSA, and the following Ka 
values have been described: 3.7 × 106 L/mol [35], 5.2 × 106 L/mol [22,36], 5.3 × 106 L/mol [37], 5.6 × 106 
L/mol [30], 8.9 × 106 L/mol [38], 2.6 × 107 L/mol [39], and 4.5 × 107 L/mol [40]. The stability of ochratoxin 
A–albumin complexes decreases in the following order: HSA > bovine > porcine > chicken > rat serum 
albumin [41–44]. 
Table 1. Stern–Volmer quenching constants (KSV; unit: L/mol) and association constants (Ka; unit: 
L/mol) of ochratoxin–HSA complexes based on fluorescence spectroscopic studies. 
Complex 
KSV (±SEM) 
[×106 L/mol] 
(Stern–Volmer Plot, 
Figure 2) 
Ka (±SEM) 
[×106 L/mol] 
(Hyperquad,  
Figure 2) 
Ka (±SEM) 
[×106 L/mol] 
(Hyperquad,  
Figure 3) 
Ka (±SEM) 
[×106 L/mol] 
(Hyperquad,  
Figure 4) 
Ka (±SEM) 
[×106 L/mol] 
(Anisotropy,  
Figure 5) 
OTB–
HSA 
0.57 ± 0.05  0.83 ± 0.08  1.38 ± 0.21  1.02± 0.13 0.92 ± 0.04  
OTC–
HSA 
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Figure 5. Fluorescence anisotropy values of ochratoxin B (OTB; 1 µM; λex = 365 nm, λem = 430 nm)
and ochratoxin C (OTC; 1 µM; λex = 380 n , λem = 444 nm) in the presence of increasing human
seru albumin (HSA) concentrations in phosphate-buffered saline (PBS, pH 7.4; ex slit = 10 nm,
e slit = 10 nm). The fluorescence anisotropy of TB and OTC did not increase further above 3 µM
HSA concentration.
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Based on fluorescence measurements, Stern–Volmer quenching constants (KSV; unit: L/mol) and
association constants (Ka; unit: L/mol) of ochratoxin–HSA complexes were determined (see details in
Section 4.2). Both OTB and OTC form highly stable complexes with HSA. Only quenching studies
proposed somewhat lower association constants; however, the other three methods showed good
correlations, suggesting approximately 106 and 107 L/mol association constants of OTB–HSA and
OTC–HSA complexes, respectively (Table 1). These data are in agreement with the previously reported
association constant for the OTB–HSA complex (Ka = 1.80 × 106 L/mol) by Perry et al. [22]. This finding
demonstrates that the stability of OTC–HSA is one magnitude higher compared to the OTB–HSA
complex (Table 1). Thus, OTB and OTC form significantly less and similarly stable complexes with
HSA than ochratoxin A, respectively. Nevertheless, even the binding affinity of OTB toward HSA
can be considered high. Based on these observations, both the absence of chlorine substituent (OTB)
and the presence of ethyl substituent (OTC) decrease the stability of ochratoxin–HSA complexes.
Previous data indicate extremely strong interaction of ochratoxin A with HSA, and the following
Ka values have been described: 3.7 × 106 L/mol [35], 5.2 × 106 L/mol [22,36], 5.3 × 106 L/mol [37],
5.6 × 106 L/mol [30], 8.9 × 106 L/mol [38], 2.6 × 107 L/mol [39], and 4.5 × 107 L/mol [40]. The stability of
ochratoxin A–albumin complexes decreases in the following order: HSA > bovine > porcine > chicken
> rat serum albumin [41–44].
Table 1. Stern–Volmer quenching constants (KSV; unit: L/mol) and association constants (Ka; unit:
L/mol) of ochratoxin–HSA complexes based on fluorescence spectroscopic studies.
Complex
KSV (±SEM)
[×106 L/mol]
(Stern–Volmer
Plot, Figure 2)
Ka (±SEM)
[×106 L/mol]
(Hyperquad,
Figure 2)
Ka (±SEM)
[×106 L/mol]
(Hyperquad,
Figure 3)
Ka (±SEM)
[×106 L/mol]
(Hyperquad,
Figure 4)
Ka (±SEM)
[×106 L/mol]
(Anisotropy,
Figure 5)
OTB–HSA 0.57 ± 0.05 0.83 ± 0.08 1.38 ± 0.21 1.02 ± 0.13 0.92 ± 0.04
OTC–HSA 0.46 ± 0.06 0.77 ± 0.11 16.02 ± 4.7 9.36 ± 2.00 6.82 ± 0.24
OTB, ochratoxin B; OTC, ochratoxin C; HSA, human serum albumin; SEM, standard error of the mean.
2.2. Spectroscopic Investigation of the Interactions of PAT, DON, and T2 with HSA
First, the HSA binding of PAT, DON, and T2 were evaluated by fluorescence quenching method.
Even high concentrations of DON and T2 (15 µM mycotoxin vs. 2 µM albumin) did not modify the
fluorescence emission spectrum of HSA (data not shown), which makes questionable their complex
formation with albumin. Interestingly, a previous study suggested the strong quenching effect of DON
on HSA [24]. Yuqin et al. [24] applied fatty acid-free HSA; however, it is unlikely that fatty acids can
cause such a large difference. In that study, the inner filter effect of DON was not corrected, and a
second peak appeared at around 450 nm [24], where a band is not typical regarding HSA or DON.
It may have resulted from the low purity of the applied protein.
PAT slightly decreased the emission signal of HSA in a concentration-dependent fashion
(Figure 6A). The inner filter effect of the mycotoxin was corrected (see in Equation (1)), therefore,
this observation suggests the interaction of PAT with HSA. The Stern–Volmer plot displayed good
linearity (Figure 6B, R2 = 0.99), the KSV value was 8.23 × 103 (±1.12 × 103) L/mol. The data analysis
with the Hyperquad2006 software also yielded a relatively low association constant (Ka = 1.38 × 104 ±
0.08 × 104 L/mol). In a previous study, somewhat higher KSV (1.40× 104 L/mol) and Ka (4.59 × 104 L/mol)
values have been reported [25]. However, Yuqin et al. did not correct the inner filter effect of the
mycotoxin, which can cause significant error in the presence of high PAT concentrations (such as 30 µM
used in that study) [25]. Another report suggests the weak interaction of PAT with bovine serum
albumin [45].
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Since PAT, DON, and T2 do not display intrinsic fluorescence, these interactions were also 
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protein matrix often induces CD bands which cannot be observed under protein‐free conditions 
[16,46,47]. These so called Cotton effects (CEs) are associated with the π–π* and/or n–π* electronic 
transitions of the guest compound. The n–π* band of the ester moiety of PAT is below 240 nm, where 
the strong masking effect of the intrinsic CD as well as UV absorption activity of HSA hampers the 
detection of induced CEs. Above 250 nm, however, PAT exhibits a π–π* type UV peak centered at 
277 nm (Figure 7). In this region, the CD signals of albumin are much weaker, allowing the study of 
the binding of the mycotoxin. Accordingly, a titration experiment was conducted, increasing the 
PAT/HSA molar ratio from zero to 3.6, but no induced CD features were observed (data not shown). 
Contrary to this, some UV spectral changes could be noticed. In relation to the protein‐free state of 
Figure 6. (A) Fluorescence emission spectrum of human serum albumin (HSA; 2 µM) in the presence
of increasing concentrations (0–15 µM) of patulin (PAT) in phosphate-buffered saline (PBS, pH 7.4).
(B) Stern–Volmer plot of PAT–HSA interaction (λex = 295 nm, λem = 340 nm; ex slit = 10 nm, em slit = 10 nm;
RLU: relative light unit).
i ti st t of P co plex is thr e orders of magnitude lower compared
to ochratoxin A–HSA (Ka ≈ 3 × 107 L/mol) [21] and approximately one it l t
l ( a 1.2 × 105 L/mol), citrinin–HSA (Ka = 2.0 × 105 L/mol), and alte nariol–HSA
(Ka = 4.0 × 105 L/mol) complexes [18–20]. N vertheless, PAT binds to HSA with si il r ffi it t
fl t i (t r rte a l t 6 104 L/mol) [27,29].
i T, DON, and T2 do not display intrinsic fluorescence, t es i ter ti l
i e employing CD and UV spectrosc py. Binding of a ligand molecule within the chiral protein
matrix often induc s CD bands which cannot be observed under protein-f ee conditions [16,46,47].
These so called Cotton effects (CEs) are associated with the pi–pi* and/or n–pi* electr nic transitions of
the guest compound. The n–pi* band of the ester moiety of PAT is below 240 nm, here the strong
masking effect of th intrinsic CD as well as UV absorption activity of HSA hampers t e det ction
of induced CEs. Above 250 nm, however, PAT exhibits a pi–pi* type UV peak cent red at 277 nm
(Figure 7). In this region, the CD signal of lbumin are much weaker, allowing the study of the
binding of the mycotoxin. Accordingly, a titration experim nt was conducted, increasing the PAT/HSA
molar ratio from zero to 3.6, but n induced CD features were observ d (data not shown). Contrary
to this, some UV spectral changes could be n ticed. I relation to the protein-free state of PAT, the
bell-shaped, symmetrical absorption band slightly broadens in the presence of HSA and displays two,
partially resolved maxima around 274 and 284 nm (Figure 7). Such a kind of band splitting can be
rationalized by the exciton theory [48–50]. If two ligand molecules are accommodated close to each
other at a common protein binding site, excited state interactions may take place between their pi–pi*
transitions resulting in two—a higher- and a lower-energy level—exciton states. Intensity of these
exciton components varies depending on the relative steric disposition of the molecules (more exactly,
the pi–pi* transition dipole moments). In our case, their almost equal amplitudes indicate that long axes
of the excitonically coupled PAT molecules bound simultaneously at the same site are orthogonal to
each other, i.e., I_ (Figure 7). In the very initial phase of the titration, the HSA binding site of PAT is
in a large molar abundance relative to the toxin concentration. Therefore, the binding equilibrium is
still shifted to the 1:1 PAT–HSA complex, and thus, the UV band shows no splitting pattern (see the
blue curve in Figure 7). Upon further increase of toxin concentration, 2:1 PAT-HSA ternary complexes
will prevail with the consequent UV band split. Seemingly, it is surprising that there is no induced
CD activity despite of the co-binding of two PAT molecules and the exciton interaction between their
conjugated pi-systems. Ternary complexes of HSA and other proteins often exhibit a characteristic
biphasic CD band pair generated by the chiral exciton coupling mechanism [47,51–53]. For such result,
however, the coupled transition dipole moments must be located in different planes. Taking into
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consideration that no induced CEs were detected, it is proposed that the pi-systems of PAT molecules
bound at the HSA site are nearly co-planar.
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can be used as a diagnostic tool for protein binding of chiral compounds owing a carbonyl moiety 
[57]. However, the spectral position of the CD bands obtained in protein‐free buffer solution and at 
high molar excess of HSA are practically the same (Figure 8). Thus, it seems that DON does not enter 
into any hydrophobic cleft of the protein. 
Figure 7. Comparison of the UV absorpti n spectra of patulin (PAT) recorded in the abs nce and presence
of 25 µM human serum albumin (HSA; pH 7.4, 25 ◦C, optical path lengt : 1 cm). A possible relative
steric arrangement of two PAT molecules at the HSA binding site is shown. Long axes of the conjugated
pi-systems are nearly perpendicular to each other, resulting in the exciton splitting of the UV band.
DON contains a conjugated carbonyl chromophore, the n–pi* transition of which is CD active,
showing a broad, positive CE above 280 nm (Figure 8). The λmax value of the n–pi* CD band of saturated
and unsaturated ketones is sensitive to the polarity of the environment [54–56]. In polar aqueous
medium, the n–pi* CD maximum of DON is at 315.5 nm, whereas it shifts to 320.5 nm in the apolar,
aprotic solvent dioxane (Figure 8). Similarly, inclusion of DON into a less polar, hydrophobic HSA
binding cavity should als shift its CD extremum to longer wavelengths. This kind of r ift can
be used as a diagnostic to l for protein binding of chiral compounds owing a carbonyl moi [57].
However, the spectral position of the CD bands obtained in protein-free buffer solution and at high
molar excess of HSA are practically the same (Figure 8). Thus, it seems that DON does not enter into
any hydrophobic cleft of the protein.
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Due to the presence of several chiral centers, T2 also exhibits intrinsic CD signals which are
associated with thepi–pi* and n–pi* electronic transitions of the ethene and ester chromophores. These CD
bands can be measured below 240 nm, and thus, do not interfere with the near-UV CD motif of HSA,
which originates from the chiral perturbation of the aromatic side chains and might be sensitive to
the binding of ligand molecules [57]. To test this option, the near-UV CD spectrum of 24 µM HSA
was monitored between 245–340 nm during the increase of toxin concentration from zero to 137 µM.
However, unambiguous and relevant spectral modifications could not be registered (data not shown).
In addition, to study whether the secondary structure of the protein is affected by the presence of T2,
the far-UV CD region was also scanned. Apart from the additive intrinsic CD contribution of the
toxin, there was no significant difference between the CD curves measured for free HSA and HSA+T2
mixture (1.5 µM HSA and 535 µM toxin; data not shown).
2.3. Effects of Mycotoxins on the Albumin Binding of Site I and II Markers Based on Ultrafiltration
Ultrafiltration experiments were carried out using (±)-warfarin (site I) and (±)-naproxen (site II)
as site markers [14]. Albumin-bound molecules are entrapped in the retentate due to the large size of
the protein; however, free (unbound) ligands pass through and consequently appear in the filtrate.
Therefore, the increased concentrations of site markers in the filtrate is resulted from their displacement
from HSA [20,58]. In a concentration-dependent fashion, both OTB and OTC significantly increased
the warfarin content in the filtrate, suggesting its displacement from the site I (Figure 9A). In line with
the case of ochratoxin A [30], the high-affinity binding site of OTB and OTC is located in subdomain
IIA. The higher displacing effect of OTC compared to OTB is in accord with the higher stability of
OTC-HSA (see in Section 2.1). However, PAT, DON, and T2 did not alter the concentration of warfarin
in the filtrate, even at 20-fold concentrations vs. the site marker. Furthermore, none of the tested
mycotoxins affected the interaction of the site II marker naproxen with HSA (Figure 9B). Previous results
validate this model since under the same experimental conditions, flavonoids chrysin, chrysin-7-sulfate,
and 7,8-dihydroxyflavone (Ka values of these albumin–ligand complexes are 2.5 × 105 to 7.6 × 105
L/mol) caused the statistically significant displacement of naproxen [58,59]. Thus, ultrafiltration studies
also confirm the strong interactions of OTB and OTC with the site I region of HSA. Furthermore,
these observations demonstrate the poor displacing ability of PAT, DON, and T2 vs. site I and II ligands.
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Figure 9. Concentration of (±)-warfarin (WAR; (A)) and (±)-naproxen (NAP; (B)) in the filtrate. Samples
contained warfarin and HSA (1.0 and 5.0 µM, respectively) or naproxen and HSA (1.0 and 1.7 µM,
respectively) with and without mycotoxins (OTB, ochratoxin B; OTC, ochratoxin C; PAT, patulin; DON,
deoxynivalenol; T2, T-2 toxin; human serum albumin, HSA; ** p < 0.01, * p < 0.05).
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2.4. Effect of Albumin on the Acute Cellular Toxicity of Mycotoxins
As has been demonstrated previously, albumin can strongly alleviate the in vitro toxic effects of
certain mycotoxins (e.g., citrinin and ochratoxin A) [18,34,60], via the limitation of their tissue uptake [35].
To test the toxicological importance of mycotoxin–albumin interactions, the cytotoxicity of OTB, OTC,
PAT, DON, and T2 were examined without and with 10% fetal bovine serum (FBS) or 40 g/L HSA on
HepG2 cells. The toxic effects of mycotoxins were evaluated employing ATP-based cell viability assay.
In the absence of albumin, mycotoxins strongly decreased ATP levels/well (Figures 10 and 11).
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Figure 10. Effects of ochratoxin B (OTB; (A)) and ochratoxin C (OTC; (B)) on adenosine triphosphate
(ATP) levels/well (% of control). HepG2 cells were incubated for 48 h in the absence and presence of 10%
fetal bovine serum (FBS) or 40 g/L human serum albumin (HSA; statistical significance compared to the
corresponding control: ** p < 0.01; compared to the effect without albumin: # p < 0.05, ## p < 0.01).
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4. Materials and Methods 
4.1. Reagents 
Patulin (PAT), deoxynivalenol (DON), T‐2 toxin (T2), human serum albumin (HSA; product 
code: A1653; containing fatty acids), racemic warfarin, racemic naproxen, and Dulbecco’s Modified 
Eagle Medium (DMEM) were purchased from Sigma‐Aldrich (St. Louis, MO, US). The 
bioluminescent ATP Assay Kit CLSII (from Roche, Basel, Switzerland) and fetal bovine serum (FBS; 
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ochratoxin C (OTC) were purchased from Cfm Oskar Tropitzsch GmbH (Marktredwitz, Germany) 
and from BioMarker Ltd. (Gödöllő, Hungary), respectively. Spectroscopic and ultrafiltration studies 
were carried out in phosphate‐buffered saline (PBS, pH 7.4). 
Figure 11. Effects of patulin (PAT; (A)), deoxynivalenol (DON; (B)), and T-2 toxin (T2; (C)) on the
cellular adenosine triphosphate (ATP) levels/well (% of control). HepG2 cells were incubated for 48 h
in the absence and presence of 10% fetal bovine serum (FBS) or 40 g/L human serum albumin (HSA;
statistical significance compared to the corresponding control: * p < 0.05, ** p < 0.01).
In agreement with previous data, OTB exerted considerably lower toxicity than OTC [4,61]. In the
presence of albumin, the toxic effects of OTB declined (Figure 10). FBS (10%, hich means
approximately 3.5 g/L bovi e serum albumin in th cell culture medium) significantly reduced and
abolished the OTB- and OTC-induced viability loss, respectively. Moreover, in the presenc of 40 g/L
HSA, the same concentrations of OTB and OTC did not affect cellular ATP levels. These results suggest
that the formation of highly stable OTB-HSA and OTC-HSA complexes diminishes the cellular uptake
of ochratoxins, indicating the significant toxicokinetic importance of these interactions.
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The cytotoxic effect of T2 was considerably higher compared to PAT or DON, which is in good
agreement with the previously reported data [62]. The presence of FBS or HSA did not affect the toxic
effects of PAT, DON, and T2 (Figure 11). In the lack of formation of high-affinity mycotoxin–albumin
complexes, albumin was unable to reduce the cellular uptake of these mycotoxins.
3. Conclusions
Based on fluorescence studies, OTB and OTC form highly stable complexes with HSA. Fluorescence
quenching and CD experiments suggest the low-affinity interaction of PAT with HSA, while DON
and T2 likely do not interact with the protein or form poorly stable complexes. In ultrafiltration
experiments, OTB and OTC significantly displaced the site I marker warfarin but other mycotoxins
tested did not affect the albumin binding either of warfarin or naproxen. Cytotoxic effects of OTB and
OTC were alleviated or even abolished in the presence of albumin, suggesting the high toxicokinetic
importance of OTB–HSA and OTC–HSA complex formations. Since albumin binding of mycotoxins
can strongly affect their tissue distribution and elimination half-life, these results may help deepen the
understanding of the toxicokinetics of mycotoxins. Cell experiments help to explore the toxicological
importance of mycotoxin–albumin interactions, because several other factors (e.g., diffusibility of
the compound and the involvement of active transport mechanisms) can also influence the cellular
uptake of mycotoxins from the circulation. Due to the complex toxicokinetics of these compounds, it is
reasonable to perform animal studies in the future for the better characterization of mycotoxin–albumin
interactions. For example, the displacement of highly albumin-bound mycotoxins (e.g., ochratoxins)
from the protein may strongly modify their toxicokinetics and toxicity.
4. Materials and Methods
4.1. Reagents
Patulin (PAT), deoxynivalenol (DON), T-2 toxin (T2), human serum albumin (HSA; product code:
A1653; containing fatty acids), racemic warfarin, racemic naproxen, and Dulbecco’s Modified Eagle
Medium (DMEM) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The bioluminescent
ATP Assay Kit CLSII (from Roche, Basel, Switzerland) and fetal bovine serum (FBS; from Pan-Biotech
GmbH, Aidenbach, Germany) were used as received. Ochratoxin B (OTB) and ochratoxin C (OTC)
were purchased from Cfm Oskar Tropitzsch GmbH (Marktredwitz, Germany) and from BioMarker Ltd.
(Gödöllo˝, Hungary), respectively. Spectroscopic and ultrafiltration studies were carried out in
phosphate-buffered saline (PBS, pH 7.4).
4.2. Fluorescence Spectroscopic Measurements
Fluorescence and UV spectra were recorded at 25 ◦C in the presence of air, employing a Hitachi
F-4500 spectrofluorometer (Tokyo, Japan) and a Specord Plus 210 spectrophotometer (Analytik Jena;
Jena, Germany), respectively. The inner filter effects of mycotoxins were corrected using the following
equation [63]:
Icor = Iobs × e(Aex+Aem)/2 (1)
where Icor is the corrected fluorescence emission intensity, Iobs is the observed emission signal, while
Aex and Aem denote the absorbance of mycotoxins at the excitation and emission wavelengths
used, respectively.
In fluorescence quenching studies, emission spectra of HSA (2 µM) were recorded in the absence
and presence of mycotoxins (final concentrations of PAT, DON and T2: 0.0, 1.5, 3.0, 5.0, 7.5, 10.0, and
15.0 µM; final concentrations of OTB and OTC: 0, 0.1, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, and 2.0 µM) using
295 nm excitation wavelength. Under the applied conditions, solvents applied (dimethyl sulfoxide or
ethanol) did not affect the fluorescence emission signal of HSA at 340 nm. Association constants (Ka)
were determined using the Hyperquad2006 software (Version 3.1.60, Protonic Software, Leeds, UK)
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by non-linear fitting, as described [23,34,64]. Data were also evaluated based on the Stern–Volmer
equation [63]:
I0
I
= 1+ KSV × [Q] (2)
where I0 is the fluorescence emission intensity of HSA without mycotoxins, I is the emission signal of
HSA in the presence of mycotoxins (λex = 295 nm, λem = 340 nm), KSV is the Stern–Volmer quenching
constant, and [Q] is the molar concentration of the quencher.
Fluorescence emission spectra of ochratoxins (1 µM) were also examined in the presence of
increasing concentrations of HSA (0–7.5 µM for OTB and 0–3 µM for OTC). The emission spectra
were recorded using 295 nm excitation wavelength, because of the energy transfer between HSA
and ochratoxins [23]. Furthermore, the fluorescence excitation wavelength maxima of OTB (365 nm)
and OTC (380 nm) were also applied, to examine the changes in the fluorescence emission signals
of ochratoxins resulting from their interaction with HSA. Association constants of OTB–HSA and
OTC–HSA complexes were determined by the Hyperquad2006 software, as have been reported
previously [23]. Fluorescence anisotropy measurements were performed with the same samples, at the
wavelength maxima of OTB (λex = 365 nm, λem = 430 nm) and OTC (λex = 380 nm, λem = 444 nm).
Anisotropy (r) values were calculated using the following equation [23]:
r =
(IVV −G× IVH)
(IVV + 2×G× IVH) (3)
where G denotes the instrumental correction factor, while IVV and IVH show the fluorescence emission
intensities determined in vertical position of polarizer at the pre-sample site and at vertical and
horizontal positions of the post-sample polarizer, respectively. Association constants were calculated
from anisotropy values as described previously [23].
4.3. Circular Dichroism (CD) and Absorption Spectroscopic Measurements
CD and UV absorption spectra were acquired at 25 ± 0.2 ◦C on a JASCO J-715 spectropolarimeter
(Tokyo, Japan) equipped with a Peltier thermostat. All spectra were monitored in continuous scanning
mode at a rate of 50 nm/min, with a step size of 0.1 nm, response time of 2 s, three accumulations and
1 nm bandwidth, using 1 or 0.1 cm path-length quartz cuvette (Hellma GmbH & Co., Plainview, NY,
USA). Absorption spectra were obtained by conversion of the high tension (HT) voltage applied to the
photomultiplier tube into absorbance units. CD and absorption curves of mycotoxin–HSA mixtures
were corrected by spectral contribution of blank HSA solutions. Albumin samples were dissolved in
PBS (pH 7.4). The concentration of HSA (MW: 66,500) was determined using its weighted amount.
Stock solutions of mycotoxins were prepared as follows: DON, 8.4 mM in deionized water; T2, 5.4 mM
in ethanol; PAT, 2.6 mM in deionized water. To test the albumin binding of PAT and T2, 1.8 mL HSA
samples were prepared at 25 and 24 µM concentrations, respectively. After recording the CD and UV
absorption spectra of free HSA, µL aliquots of the stock solutions of the mycotoxins were pipetted
consecutively into the protein sample. CD and absorption curves were scanned after addition of each
aliquot. In the case of DON, the mycotoxin was mixed into 0.36 mM HSA solution.
4.4. Ultrafiltration
To investigate the effects of mycotoxins on the albumin binding of Sudlow’s site I and II ligands,
ultrafiltration experiments were performed as described earlier [20,58]. Briefly, samples contained
warfarin–HSA (1.0 and 5.0 µM, respectively) or naproxen–HSA (1.0 and 1.5 µM, respectively) mixtures
in the absence and presence of mycotoxins (5, 10, or 20 µM) in PBS (pH 7.4). Ultrafiltration (10 min,
7500 g, and 25 ◦C) was performed using Pall Microsep™ Advance Centrifugal Devices (30 kDa
molecular weight cut-off value; VWR, Budapest, Hungary), then the concentrations of warfarin and
naproxen in the filtrate were quantified by HPLC.
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The HPLC system was built up from a Waters 510 HPLC pump (Waters, Milford, MA, USA),
a Rheodyne 7125 injector (Rheodyne, Berkeley, CA, USA) linked to a 20 µL sample loop, a Waters
486 UV detector, and a Jasco FP-920 fluorescent detector (Jasco, Tokyo, Japan). Peak areas were
evaluated employing Waters Millennium Chromatography Manager software (Version 3.2, Waters
Corporation, Milford, MA, USA). Warfarin and naproxen were quantified as described previously [20].
The limit of detection (LOD) and the limit of quantification (LOQ) were the lowest concentrations
when the signal-to-noise ratios 3 and 10 were observed, respectively. The LOD values were 0.05 µM
for both warfarin and naproxen. The LOQ values were 0.1 and 0.2 µM for warfarin and naproxen,
respectively. Both methods showed good linearity (warfarin: R2 = 0.998; naproxen: R2 = 0.999) in
the concentration range of 0.05–2.00 µM. Reproducibility was established by intraday and interday
precision. The intraday coefficients of variation values were 2.1% for warfarin and 1.0% for naproxen
(n = 7). The interday coefficient of variation values were 6.4% and 5.4% for warfarin and naproxen,
respectively (n = 5).
4.5. Cell Culturing and Viability Assay
Cell experiments were performed on HepG2 (human hepatocellular carcinoma; ATCC: HB-8065)
adherent cell line. The cells were cultured in DMEM with 10% FBS, 100 U/mL penicillin, and 100 µg/mL
streptomycin (5% CO2, 37 ◦C). Cells (104/well in 96-well plates) were treated for 48 h with OTB (5.0,
10.0 and 20.0 µM), OTC (0.05, 0.1, and 0.5 µM), PAT (1.0, 2.0, and 5.0 µM), DON (1.0, 2.0, and 5.0 µM),
and T2 (0.02, 0.25, and 1.0 µM) in the absence and presence of 10% FBS or 40 g/L HSA. ATP levels were
quantified applying the previously described method without modifications [65].
4.6. Statistics
Data demonstrate the mean and standard error of the mean (SEM) values. Assays were performed
at least in triplicate. For statistical evaluation, the one-way ANOVA (IBM SPSS Statistics, v. 21, New
York, NY, USA; p < 0.05 and p < 0.01) was applied, employing Tukey’s post hoc test.
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